Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data

Journal of Clinical Psychiatry

Volumn 67, Issue 4, 2006, Pages 638-642

  Citrome, Leslie ^a,d   Volavka, Jan ^a   Czobor, Pal ^a   Brook, Shlomo ^b   Loebel, Antony ^c   Mandel, Francine S ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sterkfontein Hospital   (South Africa)

^c PFIZER INC   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; PROPRANOLOL; TEMAZEPAM; ZIPRASIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE SYNDROME; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 33646811524     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0415     Document Type: Article

References (28)

1. Lieberman JA, Stroup ST, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
2. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184
3. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505
4. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-310
5. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
6. Citrome L, Nolan KA, Volavka J. Science-based treatment of aggression and agitation. In: Fishbein D, ed. The Science, Treatment, and Prevention of Antisocial Behaviors: Evidence-Based Practice. 1st ed. Kingston, NJ: Civic Research Institute, Inc; 2004;11.1-11.31
7. Volavka J. Neurobiology of Violence. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc; 2002
8. Hughes DH. Acute pharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999;50:1135-1137
9. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
10. Keckich WA. Neuroleptics: violence as a manifestation of akathisia. JAMA 1978;240:2185
11. Crowner ML, Douyon R, Convit A, et al. Akathisia and violence. Psychopharmacol Bull 1990;26:115-117
12. Winans EA, Janicak PG. IM olanzapine in the treatment of agitation and aggression. Expert Rev Neurother 2001;1:28-32
13. Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003;64(suppl 19):13-18
14. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24:225-228
15. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510-1514
16. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent schizophrenic and schizoaffective patients. Arch Gen Psychiatry. In press
17. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-249
18. Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2005;66:1362-1366
19. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
20. Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178:514-523
21. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
22. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
23. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-289
24. Nolan KA, Volavka J, Czobor P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J Psychiatr Res 2005;39:109-115
25. Wright P, Meehan K, Birkett M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420-1428
26. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005;27:140-144
27. Edlinger M, Hausmann A, Kemmler G, et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 2005;77:25-34
28. Mauri MC, Regispani F, Beraldo S, et al. Patterns of clinical use of antipsychotics in hospitalized psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:957-963